Related Experiment Video
Updated: Mar 14, 2026

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
Published on: July 31, 2016
Polymyxin B Direct Hemoperfusion Using Regional Citrate-Calcium Anticoagulation: A Case Report
Anna Sidoti1, Etrusca Brogi, Joshua Morse
1From the *Department of Anesthesia and Intensive Care, University of Pisa, Pisa, Italy; †McGill University, Montreal, Canada; and ‡Department of Anesthesia and Intensive Care, University of Udine, Udine, Italy.
Abstract:
Direct hemoperfusion with polymyxin B (PMX-DHP) is an extracorporeal treatment to add to conventional therapy during unresponsive endotoxic septic shock. So far, only heparin has been used as an anticoagulant during polymyxin B therapy. We present a case report of a postsurgical septic patient treated with 2 cycles of PMX-DHP using citrate anticoagulation. Monitoring of serum calcium, postcartridge calcium, and acid-base balance was performed. The treatments were accomplished without complications. To our knowledge, this is the first published report on the use of citrate anticoagulation during PMX-DHP. We conclude that citrate anticoagulation is feasible during hemoperfusion therapy in patients with increased hemorrhagic risk.
Related Concept Videos
Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Continuous Renal Replacement Therapy
Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis

